{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.5","upperLimit":"99.5","value":"96.3"},{"groupId":"OG001","lowerLimit":"60.2","upperLimit":"83.1","value":"73.6"},{"comment":"There was no PD or death occurred in this arm.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"description":"Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size.","dispersionType":"95% Confidence Interval","groups":[{"description":"PCI-32765: 420 mg daily or 840 mg daily","id":"OG000","title":"Treatment Naive"},{"description":"PCI-32765: 420 mg daily or 840 mg daily","id":"OG001","title":"Relapsed/ Refractory"},{"description":"Food-Effect Relapsed/refractory participants received PCI-32765 420 mg daily","id":"OG002","title":"Food- Effect"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).","title":"Progression Free Survival Rate at 24 Months","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}